235 related articles for article (PubMed ID: 17419150)
1. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
von Mehren M
Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S30-4. PubMed ID: 17419150
[TBL] [Abstract][Full Text] [Related]
2. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
3. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F
Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778
[TBL] [Abstract][Full Text] [Related]
6. C-kit, GIST, and imatinib.
Siehl J; Thiel E
Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
[TBL] [Abstract][Full Text] [Related]
7. [KIT and KIT: from biology to clinical use].
Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
[TBL] [Abstract][Full Text] [Related]
8. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis and management of gastrointestinal stromal tumors.
Bayraktar UD; Bayraktar S; Rocha-Lima CM
World J Gastroenterol; 2010 Jun; 16(22):2726-34. PubMed ID: 20533592
[TBL] [Abstract][Full Text] [Related]
10. KIT mutations in GIST.
Fletcher JA; Rubin BP
Curr Opin Genet Dev; 2007 Feb; 17(1):3-7. PubMed ID: 17208434
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
14. Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.
Sevinc A
Chemotherapy; 2009; 55(2):132-6. PubMed ID: 19188713
[TBL] [Abstract][Full Text] [Related]
15. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Kim EJ; Zalupski MM
J Surg Oncol; 2011 Dec; 104(8):901-6. PubMed ID: 22069175
[TBL] [Abstract][Full Text] [Related]
18. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.
Pantaleo MA; Nicoletti G; Nanni C; Gnocchi C; Landuzzi L; Quarta C; Boschi S; Nannini M; Di Battista M; Castellucci P; Fanti S; Lollini PL; Bellan E; Castelli M; Rubello D; Biasco G
J Exp Clin Cancer Res; 2010 Dec; 29(1):173. PubMed ID: 21192792
[TBL] [Abstract][Full Text] [Related]
20. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
Montemurro M; Bauer S
Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
